Innohep (Tinzaparin Sodium)

Innohep is a low molecular weight heparin used in the management of venous thromboembolism and related surgical prophylaxis.

• Deep vein thrombosis: prevention and treatment of clot formation in the deep veins of the lower extremities.
• Pulmonary embolism: prevention and treatment of embolic obstruction in the pulmonary arteries.
• Surgical thromboprophylaxis: reduction of postoperative thromboembolic events in patients undergoing major surgery.

• Tinzaparin sodium binds to antithrombin III, enhancing its inhibitory activity against factor Xa and, to a lesser extent, factor IIa (thrombin). This accelerates the inactivation of these clotting factors, leading to reduced thrombin generation and inhibition of fibrin clot formation, thereby providing anticoagulant protection.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the subcutaneous injection site.
• Bruising or hematoma: localized bleeding under the skin.
• Minor bleeding: such as gum or nosebleeds.
• Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects

• Severe bleeding: life‑threatening hemorrhage in any organ system.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated drop in platelet count with paradoxical clot risk.
• Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures.
• Allergic reaction: urticaria, angioedema, or anaphylaxis.
• Elevated liver enzymes: abnormal hepatic function tests.

Use of Innohep requires careful assessment of patient‑specific risk factors.

• Renal impairment: adjust dosing and monitor anti‑Xa levels in patients with reduced kidney function.
• Hepatic disease: consider increased bleeding risk and monitor liver function.
• Concomitant anticoagulants: avoid or closely monitor when used with other anticoagulant or antiplatelet agents.
• Pregnancy and lactation: safety not established; weigh benefits against potential risks.
• Elderly patients: increased susceptibility to bleeding; monitor closely.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium may interact with several drug classes, affecting bleeding risk or anticoagulant efficacy.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct oral anticoagulants): additive anticoagulant effect leading to severe bleeding.
• Thrombolytic agents (e.g., alteplase): heightened risk of hemorrhage.
• Neuraxial anesthesia or spinal puncture: increased chance of spinal/epidural hematoma.

Moderate Interactions (Monitor Closely)

• Antiplatelet drugs (e.g., aspirin, clopidogrel): may modestly increase bleeding tendency.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can exacerbate gastrointestinal bleeding.
• Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): may enhance mucosal bleeding.